Starbucks Corp vs GeneDx Holdings Corp — how do they compare? Starbucks Corp trades at $104.04 (market cap $119.45B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Starbucks Corp is far larger — about 66.4× GeneDx Holdings Corp's market cap, and Starbucks Corp pays a 2.37% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SBUX | WGS | |
|---|---|---|
Market Cap | $119.45B | $1.80B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $108.37 | $167.51 |
52-Week Low | $78.46 | $34.51 |
Enterprise Value | $142.14B | $1.80B |
Dividend Yield | 2.37% | — |
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $104.45, down 0.99% today, near its 52-week high with a bullish technical trend. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $37.18B in 2025, though net income fell to $1.86B, reflecting margin pressures. Analysts maintain a buy consensus with a $108.86 target, citing turnaround progress and cost-saving initiatives, including AI-driven software reductions.
SBUX's outlook is cautiously optimistic, supported by traffic growth and raised 2026 guidance, but profitability remains a concern with a high P/E of 80.01. Key risks include intense competition from Luckin Coffee and macroeconomic sensitivity. Institutional sentiment is positive, with 47% buy ratings, though investors should monitor execution on margin recovery and cost efficiency targets.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →